Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make.
Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make, explained Douglas E. Hough, PhD, from Johns Hopkins University, during a plenary session at ISPOR’s annual meeting.
Hough outlined the thought processes that impact someone’s decisions or behaviors and the implications behavioral economics could have in healthcare. He provided 5 examples of anomalies that influence behavior:
These all influence things in healthcare, such as how we fight obesity, how adherent we are to medication, physician engagement and hand offs in the emergency room, and more, Hough concluded.
Kevin Volpp, MD, PhD, of the University of Pennsylvania, discussed the 5000-hour problem, whereby even for patients with a chronic illness who see their doctor multiple times a year, there are 5000-plus hours where these patients are largely on their own. Technology is creating an enormous opportunity for population health, but it cannot work on its own.
“While the technology creates enormous new opportunities in this space, just giving people these devices by themselves is unlikely to change their behavior,” he said. “People who buy these [devices] are typically those who are already motivated and thinking about their health.”
The devices need to be part of a larger ecosystem where patients have a device that uploads information to a health system’s services and either the patient or a social supporter and the provider gets feedback and the information goes into the electronic medical record.
What will ultimately drive change, though? The relationship, said David Meltzer, MD, PhD, of University of Chicago. The literature on patient-doctor relationships has shown the importance of trust, interpersonal relationships, communication, and knowledge of the patient in the form of lower costs and better outcomes.
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More